Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer

@inproceedings{Giovanni2006ProliferationAA,
  title={Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer},
  author={Brachelente Giovanni},
  year={2006}
}

Topics from this paper.

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 67 CITATIONS, ESTIMATED 57% COVERAGE

Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010
VIEW 7 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Pre-operative Endocrine Therapy

VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2007
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations